Vijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated May 07, 2026, titled "Press Release on Q-4 Financials".
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts more than Nifty Smallcap 250 and 4.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre reported strong Q4 FY26 results with highest-ever quarterly revenue of Rs 219.3 Cr, up 26.6% YoY. Full year FY26 revenue crossed Rs 800 Cr mark at Rs 814.2 Cr, growing 19.5% YoY. EBITDA grew 38.7% YoY in Q4 to Rs 95.5 Cr with margins expanding 379 basis points to 43.5%. PAT grew 37.5% YoY to Rs 47.9 Cr in Q4, while FY26 PAT stood at Rs 173 Cr, up 20.3%. Total tests processed grew 18.5% YoY to 4.49 Mn in Q4, with average realization per test increasing 6.8% to Rs 488. The company achieved 16.5% CAGR over five years since listing, outperforming its 15% guidance.
Strong quarterly and annual performance with margin expansion indicates operational efficiency gains. Revenue crossing Rs 800 Cr milestone and robust PAT growth signal solid execution, likely positive for the stock.